Cargando…

Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey

INTRODUCTION: Alpha-mannosidosis is an ultra-rare lysosomal storage disorder resulting from the deficient activity of lysosomal alpha-mannosidase. Alpha-mannosidosis presents as a highly heterogenous condition with large variations in symptom severity and disease progression rates. Quantitative and...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam, Jacqueline, Malone, Rachel, Lloyd, Sioned, Lee, Jennifer, Hendriksz, Christian J., Ramaswami, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557729/
https://www.ncbi.nlm.nih.gov/pubmed/31198684
http://dx.doi.org/10.1016/j.ymgmr.2019.100480
_version_ 1783425480056111104
author Adam, Jacqueline
Malone, Rachel
Lloyd, Sioned
Lee, Jennifer
Hendriksz, Christian J.
Ramaswami, Uma
author_facet Adam, Jacqueline
Malone, Rachel
Lloyd, Sioned
Lee, Jennifer
Hendriksz, Christian J.
Ramaswami, Uma
author_sort Adam, Jacqueline
collection PubMed
description INTRODUCTION: Alpha-mannosidosis is an ultra-rare lysosomal storage disorder resulting from the deficient activity of lysosomal alpha-mannosidase. Alpha-mannosidosis presents as a highly heterogenous condition with large variations in symptom severity and disease progression rates. Quantitative and qualitative data for alpha-mannosidosis patients and their caregivers provide important insights into their daily experiences. METHODS: A survey of nine alpha-mannosidosis patients was carried out in the UK between August 2017 and January 2018. Patient demographics, health-related quality of life (HRQoL), and qualitative data from patients and carers relating to clinical characteristics and impact of the disease and treatment were analysed. RESULTS: At the time of survey completion, patient age ranged from 7 to 37 years. Five patients were described as ‘walking unassisted’, one as ‘walking with assistance’, one as ‘wheelchair-dependent’, and two as ‘severely immobile’. In addition to best supportive care, three patients had received haematopoietic stem cell transplantation (HSCT) and one had received velmanase alfa enzyme replacement therapy (ERT). Patient HRQoL results for the EQ-5D-5 L questionnaire and the Health Utilities Index-3 showed that patients with more severe ambulatory health states reported lower utility values than patients who were more mobile. Patients who received HSCT or ERT experienced improved HRQoL. Carer HRQoL results for the Hospital Anxiety and Depression Scale and Caregiver Strain Index demonstrated that carers experience high levels of stress and anxiety from their caregiving responsibilities. CONCLUSIONS: This survey confirmed the heterogeneity of alpha-mannosidosis and the large impact of the disease and treatment on patients, carers, and families. Early diagnosis and access to treatment offers the best chance of slowing the disease progression and may provide some relief to patients and carers.
format Online
Article
Text
id pubmed-6557729
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65577292019-06-13 Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey Adam, Jacqueline Malone, Rachel Lloyd, Sioned Lee, Jennifer Hendriksz, Christian J. Ramaswami, Uma Mol Genet Metab Rep Research Paper INTRODUCTION: Alpha-mannosidosis is an ultra-rare lysosomal storage disorder resulting from the deficient activity of lysosomal alpha-mannosidase. Alpha-mannosidosis presents as a highly heterogenous condition with large variations in symptom severity and disease progression rates. Quantitative and qualitative data for alpha-mannosidosis patients and their caregivers provide important insights into their daily experiences. METHODS: A survey of nine alpha-mannosidosis patients was carried out in the UK between August 2017 and January 2018. Patient demographics, health-related quality of life (HRQoL), and qualitative data from patients and carers relating to clinical characteristics and impact of the disease and treatment were analysed. RESULTS: At the time of survey completion, patient age ranged from 7 to 37 years. Five patients were described as ‘walking unassisted’, one as ‘walking with assistance’, one as ‘wheelchair-dependent’, and two as ‘severely immobile’. In addition to best supportive care, three patients had received haematopoietic stem cell transplantation (HSCT) and one had received velmanase alfa enzyme replacement therapy (ERT). Patient HRQoL results for the EQ-5D-5 L questionnaire and the Health Utilities Index-3 showed that patients with more severe ambulatory health states reported lower utility values than patients who were more mobile. Patients who received HSCT or ERT experienced improved HRQoL. Carer HRQoL results for the Hospital Anxiety and Depression Scale and Caregiver Strain Index demonstrated that carers experience high levels of stress and anxiety from their caregiving responsibilities. CONCLUSIONS: This survey confirmed the heterogeneity of alpha-mannosidosis and the large impact of the disease and treatment on patients, carers, and families. Early diagnosis and access to treatment offers the best chance of slowing the disease progression and may provide some relief to patients and carers. Elsevier 2019-06-08 /pmc/articles/PMC6557729/ /pubmed/31198684 http://dx.doi.org/10.1016/j.ymgmr.2019.100480 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Paper
Adam, Jacqueline
Malone, Rachel
Lloyd, Sioned
Lee, Jennifer
Hendriksz, Christian J.
Ramaswami, Uma
Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title_full Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title_fullStr Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title_full_unstemmed Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title_short Disease progression of alpha-mannosidosis and impact on patients and carers – A UK natural history survey
title_sort disease progression of alpha-mannosidosis and impact on patients and carers – a uk natural history survey
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557729/
https://www.ncbi.nlm.nih.gov/pubmed/31198684
http://dx.doi.org/10.1016/j.ymgmr.2019.100480
work_keys_str_mv AT adamjacqueline diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey
AT malonerachel diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey
AT lloydsioned diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey
AT leejennifer diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey
AT hendrikszchristianj diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey
AT ramaswamiuma diseaseprogressionofalphamannosidosisandimpactonpatientsandcarersauknaturalhistorysurvey